3 Monster Stocks to Buy Right Now With Dividend Yields of 5% or More

The article highlights three high-yield income stocks: Enterprise Products Partners at 6.1%, Pfizer at about 7.2%, and Verizon at 6.2%, all with long dividend-growth streaks. It argues that Enterprise's balance sheet and $5.3 billion pipeline under construction, Pfizer's 96-program pipeline, and Verizon's improving free cash flow and fiber expansion support their income appeal. This is primarily an investor-selection piece rather than new company-specific news, so near-term market impact should be limited.

Analysis

The setup is really a duration trade in disguise: all three names are being sold as “income,” but the market is implicitly pricing very different reinvestment and refinancing paths. EPD screens best because its cash flows are tied to volume growth and fee-based infrastructure demand, so it has a cleaner path to sustaining capital returns without depending on rate cuts. That matters in a world where high yields are otherwise competing with Treasuries; the best dividend stocks are the ones whose payout is least sensitive to funding costs and commodity volatility.

The second-order winner is the midstream ecosystem around data-center power buildout and NGL export chains. If EPD’s project backlog keeps converting, the beneficiaries are not just its own units but also compressor, storage, and industrial services names that monetize incremental throughput; conversely, smaller leveraged midstream operators remain at risk if capital markets stay tight and customers demand balance-sheet resilience. The real risk to the thesis is not demand destruction but regulatory or execution friction that delays project ramp, which would compress the yield-premium valuation before cash flow growth arrives.

Pfizer is a classic “yield now, pipeline later” situation, but the market is likely underestimating how much of the equity is being priced as a patent-cliff annuity rather than a turnaround story. The obesity asset is the key option value, yet it is still far enough out that the stock will trade mainly on whether management can bridge the 2026-2028 gap without another large guidance reset. A miss on clinical or launch timing could force dividend investors to rotate out quickly, while any credible positive readout can trigger a sharp re-rating because the stock is already anchored to a low-growth multiple.

Key Decisions for Investors

• Long EPD vs. short VZ as a relative-value income pair for 3-6 months: prefer the cleaner self-funded growth path and lower duration risk; stop if EPD project execution slips or VZ prints accelerating subscriber gains.
• Add EPD on pullbacks for a 12-month hold targeting dividend-plus-low-teens total return; risk/reward is attractive as long as balance-sheet discipline persists and project backlog converts on schedule.
• Buy PFE only as a staged position over 6-12 months, with the thesis dependent on pipeline optionality rather than current fundamentals; cap sizing because patent-cliff and trial risk can reprice the stock lower before any obesity catalyst emerges.
• Avoid chasing VZ for new capital at current levels; if owning for income, pair with a longer-duration rate hedge or consider covered calls to monetize the rich yield while limiting upside expectations.
• For diversified income exposure, rotate away from the highest-yield names that are most rate-sensitive and into the one with operating leverage to secular volume growth: overweight EPD, market-weight PFE, underweight VZ.